Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 19, Issue 3, pp. 742-754
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 2, 2019
- Revision received September 16, 2019
- Accepted November 27, 2019
- Published first December 3, 2019.
Article Versions
- Previous version (December 3, 2019 - 05:13).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Sho Nakai1,
- Hironari Tamiya2,
- Yoshinori Imura2,
- Takaaki Nakai3,
- Naohiro Yasuda1,
- Toru Wakamatsu2,
- Takaaki Tanaka2,
- Hidetatsu Outani1,
- Satoshi Takenaka1,
- Kenichiro Hamada1,
- Akira Myoui1,
- Nobuhito Araki4,
- Takafumi Ueda5,
- Hideki Yoshikawa1, and
- Norifumi Naka1,2,*
- 1Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
- 2Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
- 3Department of Orthopaedic Surgery, Kawachi General Hospital, Kawachi, Japan.
- 4Department of Orthopaedic Surgery, Ashiya Municipal Hospital, Ashiya, Japan.
- 5Department of Orthopaedic Surgery, Osaka National Hospital, Osaka, Japan.
- ↵*Corresponding Author:
Norifumi Naka, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-Ku, Osaka 541-8567, Japan. Phone: 81-6-6945-1181; Fax: 81-6-6945-1900; E-mail: naka-no{at}mc.pref.osaka.jp
March 2020
Volume 19, Issue 3
Volume 19, Issue 3
Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling
Jump to section
Advertisement